Cochrane upper gastrointestinal and pancreatic diseases group

Cochrane Upper Gastrointestinal and Pancreatic Diseases Group [Review Group]
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, Bennett C, Lilleyman J, Dearness K Contact details:Ms Jan LilleymanWorsley Building Rm 8.49University of LeedsLeeds LS2 [email protected]: +44 113 343 5419fax: +44 113 343 4877 About The Cochrane Collaboration Published in Issue 5, 2010Copyright 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
This version first published online: 15 April 2009 in Issue 2, 2009This record was last updated on: 14 April 2010 What's new
This issue (5) of The Cochrane Library 2010, contains the publication of two updated reviews. The group has a total of 46published reviews and 30 published protocols.
Updated Reviews
1. Antibiotic therapy for prophylaxis against infectionof pancreatic necrosis in acute pancreatitis, by Villatoro et al.
2. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus, by Bennett et Corrections and Withdrawals
1. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction, by Kuipers et al has been withdrawn as it has been two years since it was last updated.
2. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years, by Craig et al has been withdrawn as the authors are unable to update the review.
3. Proton pump inhibitor treatment for acute peptic ulcer bleeding, by Howden et al has been withdrawn as it has been two Editorial information
Editorial team
Co-ordinating Editor
Paul Moayyedi, Canada
Deputy Co-ordinating Editor
Grigorios Leontiadis, Canada
Managing Editor
Karin Dearness, Canada
Trials Search Co-ordinator
Racquel Simpson, Canada
Editors
Alan Barkun, Canada
Todd Baron, USA
Brendan Delaney, UK
Javier Gisbert, Spain (Feedback editor)
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Richard Malthaner, CanadaPaul Moayyedi, CanadaAlaa Rostom, CanadaFrances Tse, CanadaBenjamin Wong, China Medical Statisticians
Changchun Xie, Canada
Noori Akhtar-Danesh, Canada
Sarah Rhodes, Egypt
Secretary
No appointment
Mentor
Dr Neel Sharma MBChB, BSc (Hons)
Foundation Year One Doctor
Barts and the London NHS Trust
Whitechapel
London E1 1BB
Contact details:
Karin Dearness
McMaster University
HSC 3N51C
1200 Main Street West
Hamilton, Ontario
L8N 3Z5
Canada
Copyright 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors
Authors (also known as Reviewers) and Co-authors of published protocols and reviews. This list includes authors with
publications on this issue of the Cochrane Library and those whose reviews have expired.
Shahab Abid, PakistanAjit T Abraham, UKKeith R Abrams, UKRadamés Isaac Adefna Pérez, CubaNadeem Afzal, UKMarjan Aghazahedi, CanadaJawad Ahmad, UKUsama Ahmed Ali, NetherlandsAli Ajaz, UKHakima Al-Hashimi, BahrainWaleed Al-Hazzani, CanadaMamun Al-Mahtab, BangladeshMohammed Al-Omran, Saudi ArabiaAhmed Al-asfoor, BahrainSuhail Alam, UKVictor Alberto, UKDerek Alderson, UKAli Alhamdani, UKDunia Alhashimi, BahrainCarlos Almeida, BrazilRégis B Andriolo, BrazilGerd Antes, GermanyCarlos Aravena, ChileDavid Armstrong, CanadaSydney J Arnott, UKÁlvaro N Atallah, BrazilCristina Augood, UKVicente B Avanzado, PhilippinesKhurram Ayub, UKAnoop Babu, UK Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Additional contributors
Peer referees of published protocols and reviews
We would like to thank those named below for acting as peer referees to the reviews and protocols published in the UGPDGroup's module in The Cochrane Library. We are extremely grateful for your time, knowledge and help.
Jacqueline R Dalby-Payne, AustraliaAnne Duggan, AustraliaGlyn Jamieson, AustraliaPhilippa Middleton, AustraliaJames Toouli, AustraliaTristan Yan, AustraliaJan Tack, BelgiumYvan Vandenplas, BelgiumErik de Koster, BelgiumDavid Armstrong, CanadaAlan Barkun, CanadaJeffery Barkun, CanadaNaoki Chiba, CanadaDeborah Cook, CanadaCarlo Fallone, CanadaRichard Finley, CanadaGabriela Ghitulescu, CanadaRobert Issenman, CanadaLiisa Jaakkimainen, CanadaGrigorios I Leontiadis, CanadaFabio Luison, CanadaRichard Malthaner, CanadaSerge Mayrand, CanadaPaul Moayyedi, CanadaSander van Zanten, CanadaChun-Tao Che, ChinaJianjun Du, ChinaP Sun, ChinaJoseph J Y Sung, ChinaC N Tang, ChinaPeter Matzen, DenmarkPeer Wille-Jørgensen, DenmarkThierry Conroy, FranceChristian Gouillat, FranceCarmelo Lafuente-Lafuente, FranceHans Beger, GermanyNorbert Bethge, GermanyMarkus W Büchler, GermanyMarius Distler, GermanyArno Dormann, GermanyRainer Isenmann, GermanyKlaus Linde, GermanyChristoph M Seiler, GermanyChris Dervenis, GreeceC Karalambos Gogos, GreeceTheodore Rokkas, GreeceEliza Wong, Hong KongShailu V Shrikhande, IndiaBilly Bourke, IrelandBrendan Drumm, IrelandSeamus O'Mahony, IrelandColm A O'Moráin, IrelandAngelo Andriulli, ItalyFederico Bozzetti, ItalyMassimo Falconi, ItalyFrancesco Fiorica, ItalyIrene Floriani, ItalyLaurino Grossi, Italy Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Tom Jefferson, ItalyDomenico Palli, ItalyRaffaele Pezzilli, ItalyVincenzo Savarino, ItalyAnnamaria Staiano, ItalyVincenzo Valentini, ItalyMasaharu Tatsuta, JapanJae-Moon Bae, Korea, SouthSK Myung, Korea, SouthAlbert Bredenoord, NetherlandsMarco Bruno, NetherlandsAnnemiek Cats, NetherlandsJan Dees, NetherlandsHenk Festen, NetherlandsErnst J Kuipers, NetherlandsRobert Laheij, NetherlandsAd Masclee, NetherlandsNanno H Mulder, NetherlandsMattijs E Numans, NetherlandsErik Rauws, NetherlandsPeter D Siersema, NetherlandsM Sinaasappel, NetherlandsAndre Smout, NetherlandsNiek J de Wit, NetherlandsCasper van Eyck, NetherlandsLieke van Kerkhoven, NetherlandsIain Martin, New ZealandJan Hatlebakk, NorwayStanislaw Klek, PolandMarek Olakowski, PolandMohammad Sultan Khuroo, Saudi ArabiaAgustin Balboa, SpainXavier Calvet, SpainFernando Carballo, SpainEnrique Dominguez-Muñoz, SpainFast Feu, SpainVincente Garrigues, SpainJavier P Gisbert, SpainAngel Lanas, SpainMiguel Perez-Mateo, SpainEnrique Quintero, SpainEnrique Rey, SpainEnrique Vazque-Sequeiros, SpainJorg Melzer, SwitzerlandReinhard Saller, SwitzerlandDerek Alderson, UKStephen E Attwood, UKKhurram Ayub, UKChandu Bardhan, UKJohn N Baxter, UKJane Blazby, UKDeclan Carey, UKRichard M Charnley, UKDuncan Colin Jones, UKDavid Cunningham, UKJohn DeCaestecker, UKJonathan J Deeks, UKBrendan Delaney, UKMartin Dennis, UKEdzard Ernst, UKJohn Fielding, UKElizabeth Gardener, UKRuth E Gilbert, UKJames Gildersleve, UKAndrew Goddard, UKHugh Grant, UK Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Sheila Greenfield, UKMike Griffin, UKKurinchi Selvan Gurusamy, UKPeter Harper, UKChristopher J Hawkey, UKRobert Heading, UKPali Hungin, UKGeorge Jacob, UKJanusz Jankowski, UKDavid Kirby, UKMike Larvin, UKKenneth EL McColl, UKCliodna McNulty, UKJack Miller, UKGeorge (JJ) Misiewicz, UKJohn Neoptolemos, UKKelvin R Palmer, UKJohn N Primrose, UKGregory Rubin, UKBhupinder Sandhu, UKShelly Soo, UKCatherine Spinou, UKWill Steward, UKLigy Thomas, UKAlastair Thompson, UKJayne Tierney, UKPeter Watson, UKSimon Wessely, UKChris Williams, UKJohn A Carr, USATom R DeMeester, USAGary W Falk, USARonnie Fass, USALori Fischbach, USAMark Gilger, USADarell Heiselman, USAPeter Kahrilas, USAPhil Katz, USAJohn G Lee, USAAndrew M Lowy, USAWeidong Lu, USAJonathan E Markowitz, USASeamus J Murphy, USASusan R Orenstein, USAGretchen Purcell, USAJoel Richter, USARichard Sampliner, USANicholas J Talley, USAVasu Tolia, USASanthi Vege, USADouglas A Drossman Handsearchers
Supporting Cochrane Centre
Canada
Acknowledgements
The UGPD group acknowledge the invaluable contribution of David Forman (former Co-ordinating Editor), Jan Lilleyman and
Cathy Bennett (former Managing Editors), Jo Webb and Iris Gordon (former Trials Search Co-ordinators), Elizabeth Gardener
(former Statistical Editor), and Gemma Sutherington (former Administrative Assistant).
We also thank Robin Waxman for her proof reading assistance, and for her unique database design skills.
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Contributors to the Specialised Register: Adam Harris, UK - donation of database of trialsRichard Hunt (Dr J Huang), Canada - donation of databases of trialsJean Paul Galmiche, France - donation of extensive reference list We gratefully acknowledge the support of the Cochrane Cancer Network in the location of trials, peer referees and generalsupport.
The Meta Analysis Group of the MRC Trials Office, Cambridge UK converted an individual patient data review of pre-operative radiotherapy in operable cancer of the oesophagus (on behalf of the Oesophageal Cancer Collaborative Group).
Our thanks to Pat Spoor, Ros Dunlevey, Deirdre Andre, and Rosemary Campbell-Blair of LUCID Health at Leeds UniversityLibrary, for their searching expertise.
Sources of support
External sources of support
AstraZeneca (Systematic Reviews Workshop on H. pylori eradication, June 1999), UKNHS Research and Development Programme (Core Support), UKGlaxo Wellcome (Exploratory Meeting, October 1996), UKNHS HTA Programme (Systematic Reviews of Management of Non-Ulcer Dyspepsia), UKOxfordshire Health Authority Charitable Fund (Systematic Review), UKAstra (Exploratory Meeting, October 1996), UK Internal sources of support
Consumer involvement
Consumer representative: Mr David Kirby (Oesophageal Patients Association, UK)Any relevant involvement by consumers (people with the relevant health care condition, their carers, policy makers, healthprofessional, and others who may make use of the reviews prepared by the CRG) is welcomed by the UGPD Group. Atpresent, consumers act as peer referees for protocols and reviews which have been prepared by the UGPD Group. However,we intend to expand the role of consumers, possibly to include production of patient support and information leaflets, andwelcome enquiries from interested parties.
Involvement of other users
Conflict of interest
Background
Discussions concerning the formation of an Upper Gastrointestinal (GI) Cochrane Review Group (CRG) began in 1993, whena number of meetings were held to develop the work of the Cochrane Collaboration in GI disease in general. These led to theformation of the Inflammatory Bowel Disease (IBD) CRG and the Hepatobiliary CRG. It was clear that there was also a needfor a CRG in upper GI disease, not least because of the enormous health service costs involved in the clinical management ofdyspepsia, and the burgeoning number of clinical trials of variable quality.
Professor David Forman, now Co-ordinating Editor of the UGPD Group, has a long established research interest in the clinicalimpact of Helicobacter pylori infection. This seemed to be a subject that demanded methodologically robust review if it was tolead to meaningful and practical conclusions for doctors and their patients.
A "Dyspepsia CRG" exploratory meeting took place on 16th October 1996 in Copenhagen. All those who had contacted theCochrane Collaboration with an interest in this area of medicine were invited. Also present were people known to have aninterest in reviews of dyspepsia, representatives of the IBD and Hepatobiliary CRGs, the Cochrane Cancer Network, and thetwo pharmaceutical companies (Glaxo-Wellcome and Astra Hassle), who had agreed to support the event. The meeting waschaired by Andy Oxman on behalf of the Collaboration.
There was unanimous and enthusiastic support in favour of establishing a CRG, although it was felt that the scope of theGroup should also include all diseases of the oesophagus, stomach and duodenum (including malignancies). To reflect thiswidened scope, a provisional title of "Oesophageal, Gastric and Duodenal Diseases CRG" was adopted. It was agreed thatThe University of Leeds should be the editorial base and that Professor Forman should be the prospective Co-ordinatingEditor.
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group The name changed again in February 1998 to Upper Gastrointestinal and Pancreatic Diseases Group (UGPD), to reflect theintegration of pancreatic diseases into the scope of the Group.
Formal registration of the UGPD Group took place on 1 June 1998.
The editorial base for the UGPD group at Leeds University (UK) closed on March 31, 2010 at which time the Satellite UGPDgroup at McMaster University in Canada became the main editorial base, with Professor Paul Moayyedi as Co-ordinatingEditor.
Cochrane UGPD Group Editors' Meetings
1. 16th November 1999, at the Osservatorio Epidemiologico Regionale, Rome.
2. 27th November 2000, UEGW Meeting, in Brussels, Belguim.
3. 21st May 2001, DDW Meeting, Atlanta, US.
4. 20th May 2002, DDW Meeting, San Francisco, US.
5. 20th May 2003, DDW Meeting, Orlando, US.
6. 16th May 2005, DDW Meeting, Chicago, US.
"To use evidence from randomised controlled trials to answer practical questions of the prevention, treatment andrehabilitation of benign and malignant disorders of the oesophagus, stomach, duodenum and pancreas. Systematic reviews ofother types of trials will be used where necessary." ,. OtherCochrane Review Groups (CRGs) which share a potential common interest include those which address interventions whichmay have an effect on the upper gastrointestinal system (for example, NSAIDs in musculoskeletal problems). Every attemptwill be made to ensure that duplication of work does not occur and that support is given to other CRGs who wish to takeresponsibility for review topics where there is mutual interest. In particular, we would aim to support CRGs by suggesting peerreferees and by searching our specialised register for appropriate trials. All interventions (surgical, pharmacological,educational, psychological etc.) for prevention, treatment (acute and maintenance) and rehabilitation will be covered.
The CRG's policy on outcome variables is under development. Many reviews will include death, recurrence of illness,improvement of symptoms, or eradication of Helicobacter pylori as an outcome.
Glossary
Specialised register
Inclusion criteria
The specialised register for the group includes reports of trials in any language, in the prevention, treatment and rehabilitation
of benign and malignant diseases of the upper gastrointestinal tract including disorders of the oesophagus, stomach,
duodenum and pancreas.
Gastrointestinal adverse effects of certain treatments, for example NSAIDs, are also included in the register of clinical trials.
Oesophageal and gastric varices are included by the Hepato-Biliary group, pancreatic complications of cystic fibrosis arecovered by the Cystic Fibrosis Group and these are therefore not included in the UGPD register. A full list of the subjects thatare covered by the group's specialised register is given in the Topics list.
Search strategies for the identification of studies
Electronic searches
The UGPD Group searches The Cochrane Controlled Trials Register to identify controlled clinical trials for inclusion in the
specialised register. Handsearching of specialist journals and conference proceedings are being carried out to uncover further
studies. Relevant unpublished studies will be included where available.
The UGPD Group Search Strategy for The Cochrane Controlled Trials Register has been derived from MeSH subjectheadings of digestive system diseases and surgical procedures, which are relevant to the scope of the Group. Appropriatefree text terms have been used in conjunction with the MeSH headings to identify reports of randomised and controlled clinicaltrials. This strategy is under development and further search terms will be added to ensure that all trials relevant to the scopeof the UGPD Group are retrieved.
In particular, further work is required to ensure that treatments and all surgical interventions for the upper gastrointestinal tractand the pancreas are adequately covered by the search terms.
The Cochrane Controlled Trials Register is searched quarterly, after each new issue of the Cochrane Library, using thefollowing strategy. Staff at the UGPD entity have recently update the search strategy and register and are simultaneouslypublishing an updated register with this module (XXXX 2010).
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group 1. ESOPHAGEAL MOTILITY DISORDER$.sh.
2. (GERD or GORD).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]3. ((GASTRO-OESOPHAGEAL or GASTRO-ESOPHAGEAL or GASTROESOPHAGEAL) adj2 REFLUX).mp. [mp=title,abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]4. ESOPHAGITIS$.sh.
5. (OESOPHAGITIS or ESOPHAGITIS).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]6. or/1-57. ESOPHAGEAL-NEOPLASMS.sh.
8. (OESOPHAG$ or ESOPHAG$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]9. (NEOPLASM$ or CANCER$ or CARCIN$ or MALIGNAN$ or TUMOUR$ or LYMPHOMA).sh.
10. 7 or (8 and 9)11. (STRICTURE or NARROW$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]12. 11 and 813. ACHALASIA.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,drug manufacturer name]14. (SPHINCTER adj PRESSURE).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]15. 13 or (14 and 8)16. (DYSMOTILITY or MOTILITY).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]17. 16 and 818. Diverticulum, Esophageal.sh.
19. DIVERTIC$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,drug manufacturer name]20. 18 or (19 and 8)21. (RING* and WEB*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]22. ((FUNGAL or VIRAL or BACTERIAL or PARASITIC) and (INFECTION or INFECTIONS)).mp. [mp=title, abstract, subjectheadings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]23. (21 or 22) and 824. 6 or 10 or 12 or 15 or 17 or 20 or 2325. ESOPHAGEAL PERFORATION$.sh.
26. (PERFORAT$ or RUPTURE$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]27. (MALLORY adj WEISS).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]28. 27 or 25 or (8 and 26)29. HEMATOMA.sh.
30. (HAEMATOMA or HEMATOMA).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]31. (29 or 30) and 832. ESOPHAGEAL ATRESIA.sh.
33. HERNIA HIATAL.sh.
34. (HERNIA and HIAT$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]35. 32 or 33 or 3436. ESOPHAGEAL STENOSIS.sh.
37. ESOPHAGEAL FISTULA.sh.
38. 36 or 3739. FISTUL$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,drug manufacturer name]40. OBSTRUCTION.mp.
41. FOREIGN BOD$.sh.
42. 8 and (39 or 40 or 41)43. 28 or 31 or 35 or 38 or 4244. 24 or 4345. HELICOBACTER PYLORI.sh.
46. PEPTIC ULCER$.sh.
47. upper gastrointestinal tract/ or duodenum/ or esophagus/ or stomach/48. ULCER$.mp.
49. ZOLLINGER-ELLISON.mp.
50. 46 or 49 or (47 and 48) Cochrane Upper Gastrointestinal and Pancreatic Diseases Group 51. STOMACH NEOPLASMS.sh.
52. 51 or (9 and 47)53. STOMACH DISEASES$.sh.
54. gastritis/ or gastritis, atrophic/55. MENETRIER$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]56. (INTESTINAL and METAPLASIA).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]57. 53 or 54 or 55 or 5658. (ATROPHY or POLYP$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]59. Hamartoma/ or Ischemia/ or Lipoma/ or Liposarcoma/60. 47 and (58 or 59 or 22)61. POSTGASTRECTOMY SYNDROME$.sh.
62. (DUMPING adj2 SYNDROME).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]63. 57 or 60 or 61 or 6264. CELIAC DISEASE.sh.
65. WHIPPLE DISEASE.sh.
66. Sprue, Tropical.sh.
67. LACTOSE INTOLERANCE.sh.
68. (CELIAC or WHIPPLE* or (TROPICAL and SPRUE) or (LACTOSE and INTOLER*)).mp. [mp=title, abstract, subjectheadings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]69. 64 or 65 or 66 or 67 or 6870. GASTROINTESTINAL HEMORRHAGE$.sh.
71. (HEMORRHAGE or HAEMORRHAGE or BLEED or REBLEED).mp. [mp=title, abstract, subject headings, heading word,drug trade name, original title, device manufacturer, drug manufacturer name]72. Punctures/ or rupture/73. 70 or ((71 or 72) and (47 or 8))74. DUODENAL DISEASES.sh.
75. AFFERENT-LOOP SYNDROME.sh.
76. 74 or 7577. DYSPEPSIA.sh.
78. GASTROPARESIS.mp.
79. (REFLUX or EROSION).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]80. 79 and 4781. 77 or 78 or 8082. 44 or 45 or 50 or 52 or 63 or 69 or 73 or 76 or 8183. Endoscopy, Digestive System.sh.
84. DUODENOSCOPY.sh.
85. GASTROSCOPY.sh.
86. ESOPHAGOSCOPY.sh.
87. Cholangiopancreatography, Endoscopic Retrograde.sh.
88. (ERCP or (ENDOSCOPIC and RETROGRADE and CHOLANGIOPANCREATOGRAPHY)).mp. [mp=title, abstract, subjectheadings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]89. ENDOSCOP*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, devicemanufacturer, drug manufacturer name]90. 89 and (47 or 8)91. (DUODENOSCOP* or GASTROSCOP*).mp. [mp=title, abstract, subject headings, heading word, drug trade name,original title, device manufacturer, drug manufacturer name]92. 90 or 9193. 83 or 84 or 85 or 86 or 87 or 88 or 9294. FUNDOPLICATION.sh.
95. FUNDOPLICATION.mp.
96. 94 or 9597. DILATATION.sh.
98. BALLOON DILATATION$.sh.
99. ((EDER-PEUSTOW or CELESTIN or BALLOON) and DILATATION).mp. [mp=title, abstract, subject headings, headingword, drug trade name, original title, device manufacturer, drug manufacturer name]100. 8 and (97 or 98 or 99)101. DUODENOSTOMY.sh.
102. ESOPHAGECTOMY.sh.
103. ESOPHAGOPLASTY.sh.
104. ESOPHAGOSTOMY.sh.
105. (ESOPHAGOGASTRECTOMY or OESOPHOGASTRECTOMY).mp. [mp=title, abstract, subject headings, heading word, Cochrane Upper Gastrointestinal and Pancreatic Diseases Group drug trade name, original title, device manufacturer, drug manufacturer name]106. GASTRECTOMY.sh.
107. (ENDOSCOPIC and MUCOSAL and RESECTION).mp. [mp=title, abstract, subject headings, heading word, drug tradename, original title, device manufacturer, drug manufacturer name]108. 101 or 102 or 103 or 104 or 105 or 106 or 107109. (BILROTH or ROUX-EN-Y).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]110. Anastomosis, Roux-en-Y.sh.
111. VAGOTOMY*.sh.
112. (VAGOTOMY and (GASTROENTEROSTOMY or PYLOROPLASTY)).mp. [mp=title, abstract, subject headings, headingword, drug trade name, original title, device manufacturer, drug manufacturer name]113. GASTROENTEROSTOMY*.sh.
114. 109 or 110 or 111 or 112 or 113115. GASTROPLASTY.sh.
116. GASTROSTOMY.sh.
117. JEJUNOSTOMY.sh.
118. (GASTROJEJUNOSTOMY or JEJUNOSTOMY).mp. [mp=title, abstract, subject headings, heading word, drug tradename, original title, device manufacturer, drug manufacturer name]119. 115 or 116 or 117 or 118120. 108 or 114 or 119121. 82 or 93 or 96 or 100 or 120122. ANTI-ULCER AGENTS.sh.
123. (ANTIULCER adj AGENT*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]124. (ANTI-ULCER adj AGENT*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]125. 122 or 123 or 124126. HISTAMINE H2 ANTAGONISTS.sh.
127. (HISTAMINE adj2 ANTAGONIST*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]128. (RECEPTOR* adj2 ANTAGONIST*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]129. CIMETIDINE.sh.
130. FAMOTIDINE.sh.
131. NIZATIDINE.sh.
132. RANITIDINE.sh.
133. (CIMETIDINE or FAMOTIDINE or NIZATIDINE or RANITIDINE).mp. [mp=title, abstract, subject headings, heading word,drug trade name, original title, device manufacturer, drug manufacturer name]134. 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133135. OMEPRAZOLE.sh.
136. (PROTON adj PUMP adj2 INHIBITOR*).mp. [mp=title, abstract, subject headings, heading word, drug trade name,original title, device manufacturer, drug manufacturer name]137. (PROTON adj PUMP adj2 BLOCKER*).mp. [mp=title, abstract, subject headings, heading word, drug trade name,original title, device manufacturer, drug manufacturer name]138. (OMEPRAZOLE or LANSOPRAZOLE or PANTOPRAZOLE or RABEPRAZOLE).mp. [mp=title, abstract, subjectheadings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]139. 135 or 136 or 137 or 138140. (PROKINETIC adj2 AGENT*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]141. (ERYTHROMYCIN or DOMPERIDONE or METOCLOPRAMIDE or CISAPRIDE).mp. [mp=title, abstract, subjectheadings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]142. ERYTHROMYCIN.sh.
143. DOMPERIDONE.sh.
144. METOCLOPRAMIDE.sh.
145. 140 or 141 or 142 or 143 or 144146. ALGINATES.sh.
147. ALUMINUM HYDROXIDE.sh.
148. (ALGICON or ALGINATE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]149. CALCIUM CARBONATE.sh.
150. MAGNESIUM HYDROXIDE.sh.
151. MAGNESIUM OXIDE.sh.
152. SODIUM BICARBONATE.sh.
153. 146 or 147 or 148 or 149 or 150 or 151 or 152154. (ALTACITE* or ASILONE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name] Cochrane Upper Gastrointestinal and Pancreatic Diseases Group 155. (GASTROCOTE* or GAVISCON*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]156. (HYDROTALCITE* or MAALOX*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]157. MUCAINE.mp.
158. 154 or 155 or 156 or 157159. (ALUMIN* adj HYDROXIDE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]160. (CALCIUM adj CARBONATE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]161. (MAGNESIUM adj HYDROXIDE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]162. (MAGNESIUM adj OXIDE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]163. (MAGNESIUM adj TRISILICATE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]164. (SODIUM adj2 BICARBONATE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]165. (SODIUM adj2 CARBONATE*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,device manufacturer, drug manufacturer name]166. 159 or 160 or 161 or 162 or 163 or 164 or 165167. CARBENOXOLONE.sh.
168. MISOPROSTOL.sh.
169. SUCRALFATE.sh.
170. (MUCOSAL and PROTECTING and AGENT*).mp. [mp=title, abstract, subject headings, heading word, drug trade name,original title, device manufacturer, drug manufacturer name]171. (CARBENOXOLONE or MISOPROSTOL or SUCRALFATE).mp. [mp=title, abstract, subject headings, heading word,drug trade name, original title, device manufacturer, drug manufacturer name]172. 167 or 168 or 169 or 170 or 171173. MUSCARINIC ANTAGONISTS.sh.
174. DICYCLOMINE.sh.
175. PIRENZEPINE.sh.
176. PROPANTHELINE.sh.
177. ANTIMUSCARINIC*.mp.
178. (MUSCARINIC adj2 ANTAGONIST*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, originaltitle, device manufacturer, drug manufacturer name]179. (DICYCLOMINE or METHANTHELINE or PIRENZEPINE).mp. [mp=title, abstract, subject headings, heading word, drugtrade name, original title, device manufacturer, drug manufacturer name]180. PROPANTHELINE.mp.
181. 173 or 174 or 175 or 176 or 177 or 178 or 179 or 180182. 125 or 134 or 139 or 145 or 153 or 158 or 166 or 172 or 181183. 121 or (182 and (47 or 8)) Hand searching
The UGPD has registered with the US Cochrane Centre their intention to handsearch the following specialist journals:
Journals:
Alimentary Pharmacology and TherapeuticsCanadian Journal of GastroenterologyClinical Gastroenterology and HepatologyDigestive EndoscopyDiseases of the EsophagusEuropean Journal of Gastroenterology & HepatologyGastrointestinal Endoscopy Clinics of North AnericaHelicobacterPancreasNeurogastroenterology and MotilityThe Turkish Journal of Gastroenterology Conference Proceeding:
Digestive Disease Week. 1997 May 11-14; Washington DC.
Journals being handsearched by the Biomed project for the UGPD GroupThe Biomed handsearching project is a three year project in which seven European Cochrane Centres collaborate tohandsearch western European specialized health care journals. The Biomed project has undertaken to handsearch thefollowing journals on behalf of the UGPD group: Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Acta EndoscopiaActa Gastro-enterologica BelgicaAnnales de Gastroenterologie et d'HepatologieChirurgia GastroenterologicaChirurgische Gastroenterologie Endoskopie HeuteGastrum Patologia del Aparato Digestva. Gastro-Enterologie Clinique et BiologieGastro-Enterologia y HepatologiaGastroenterologisches JournalItalian Journal of Gastroenterology and HepatologyRevisiones en Gastroenterologia. Revista Andaluza de Patologia DigestivaRevista de la Asociacion Castellana del Aparato DigestivoRevista Espanola de Enfermedades DigestivasRevue Francaise de Gastro-enterologieSociedad Valenciana de Patologia Digestiva Other strategies
For each review a search strategy is produced based on relevant clinical terms agreed by the author and the Trials Search
Co-ordinator. The search strategy is constructed using a combination of Mesh terms and free text terms. All reports of
randomised controlled trials identified whilst searching will be added to the Group's Specialised Register. Where applicable,
the following information sources are searched using an individual search strategy developed for each review:
The Cochrane LibraryMedlineEmbaseCinahlWeb of ScienceLILACS PsychINFOAMED The UGPD Group has been fortunate to receive bibliographies from Adam Harris (UK), Richard Hunt (Canada) and Jean PaulGalmiche (France), which have been searched and the relevant trials added to our specialised register.
Planned searching activities
We have identified several non-English language journals and conference proceedings which we feel may contain reports of
trials relevant to our Group. These include Japanese Journal of Gastroenterology, Gastroenterological Society of Taiwan
Journal, Endoskopie Heute, and many others. However, at present we are unable to identify handsearchers for these,
accordingly we have not registered them on the Cochrane Handsearching Masterlist. If you are able to help us with searching
non-English language journals, please contact our Trials Search Co-ordinator.
Methods used in reviews
Search strategies
Access to specialised register by authors
The specialised register is available for all authors to consult through the Cochrane Library. However, to avoid duplication of
searching activities and to provide authors with a comprehensive search of the database, the Trials Search Co-ordinator will
liaise with authors to construct and develop search strategies for each review, to be carried out at the editorial base. Searches
for updating reviews will be carried out at the editorial base by the Trials Search Co-ordinator on an annual basis.
Additional search strategies
The Trials Search Co-ordinator will work with the author to create a specific search strategy for each author, which will then be
run in EMBASE and MEDLINE in addition to the Cochrane Library. The UGPD Group also liaises with the Cancer Network
when searching for authors with cancer related topics. In order to identify unpublished trials, experts in the field and
pharmaceutical companies will be contacted for information, and, where applicable, the Internet will also be searched. Reports
of trials found by these methods will be added to the UGPD register of trials. Authors should search citations in each trial
report for additional trials.
Study selection
The UGPD Group recommends that the trials included are randomised, pseudorandomised or controlled clinical trials which
compare the test intervention with placebo or standard treatment. Other types of trials can be used where necessary.
Selection of studies for inclusion in a review should be performed independently by more than one author. The editorassigned to the review will work to resolve differences in study selection between authors.
Assessment of methodological quality
Procedures for the assessment of methodological quality are under development.
Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Advice on standard criteria for assessing quality will be given by the editorial team. Examples of quality assessment checklistsare available. Methods are described in the Cochrane Authors Handbook which is available from the editorial team, on theCochrane library and via the Cochrane Web sites.
An accepted method of quality assessment should be used.
Quality should be independently assessed by more than one author and the level of agreement should be reported inthe review.
The editor responsible for the development of the review will resolve difference in quality assessment between authors.
Quality assessment will be reported in the methods and results sections of the review.
Data collection
The UGPD group recommends that the extraction of data is done independently by more than one author. The editor
responsible for the development of the review will resolve difference in data interpretation between authors. Data verification
with the person responsible for the study will not normally be required other than where the data is unpublished or
confirmation of results are required.
Data from RCTs that have not been published will be eligible for use in systematic reviews prepared by the UGPD group,subject to verification of data by the primary investigator. The UGPD Group will not routinely collect and analyse data on rareadverse events collected from non-RCTS.
The UGPD group will request copies of data extraction forms (for included studies) to be submitted to the group when a draftreview is submitted for peer referee. Data extraction forms will be retained by the group, for reference or to aid a futurereview updater, should an initial review author not be able to update a review. Data extraction forms will not be published norused in any other way by the group or its members.
Analysis
Statistical guidance is available from the editorial base (Statistical Editor: Noori Akhtar-Danesh).
Data entry to RevMan should be done using the double data entry facility which allows more than one author to independently
enter dataPolicies on statistical methods are under development.
These will incorporate guidance derived from Section 9 of the Authors Handbook on analysing data and undertaking meta-analyses.
Heterogeneity of trials and issues such as crossover trials will be addressed.
Reporting of reviews
Discussion and conclusions section
The strength of the evidence should be categorised using the hierarchy of evidence scale detailed in CRD report 4, available
from the editorial base.
The applicability of the results should be commented on taking into account the applicability of the trials to use of theintervention in standard practice for treatment of the disorder. Cost benefit analysis will not be routinely performed.
The use of non-RCT derived data when discussing results and drawing conclusions should be commented on in this section.
Where applicable, other reviews will be cross-referenced in this section.
Tables and figuresInformation in the excluded and excluded trials tables should be brief and structured to include the Study Identifier, Methods ofthe Trial, Participants, Interventions, Outcomes, and further Notes.
Each included study should ideally include a "Risk of bias" table including information on each study's and/or individualoutcomes for bias from: sequence generation; allocation concealment; blinding; incomplete data, selective reporting or othermeans.
Studies in the excluded trials table should consist of those trials which were initially selected for assessment, but which laterproved to be non-RCTs or ineligible for other reasons. Advice is available from the editorial team on the validity of trials forinclusion into the review.
Table of comparisons
Policies for the structure or order of outcomes are under development and depend to some extent on the outcomes we select
as 'default' for this group.
The order of trials in the tables will be alphabetical, then by date. Trials will be named preferably by author surname (e.g.
Smith 1998) or, where this is not possible, by trial group identifiers (e.g. Oesophageal Cancer Trials Collaborators GroupOCTCG 1997).
There may be multiple publications from one trial. Such reports should be cross referenced to the original study, for example, Cochrane Upper Gastrointestinal and Pancreatic Diseases Group a publication by Jones et al reporting data from the Oesophageal Trials Collaborators Group study of 1997, should bereported as Jones 1999 (OCTCG 1997).
Any factors which could be perceived as conflict of interest should be stated.
Editorial process
Titles
Review authors are invited to submit tiles at any time. In order to reduce the risk of wasted effort, a title should always be
registered with the Editorial Base before the review author starts work.
The preferred format is: [Intervention] in [disorder], and may specify in which population e.g. older people.
Newly registered titles will be publicised throughout the Cochrane Collaboration with the aim of increasing awareness of areasof potential common interest.
Protocols are normally expected within 6 months of acceptance of a title.
If more than one person proposes doing the same review then the UGPD Group will invite both persons to co-operate in thepreparation of the review, either by working together, or by independently analysing data and comparing the results. The Co-ordinating Editor will work with the authors to resolve disagreements about authorship of a review.
Protocols
The UGPD Group editorial team supports authors in the preparation of protocols by providing methodological advice,
formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials
such as the handbook for authors and training and support as required on an ad hoc basis. Informal advice is available
through the Review Group Co-ordinator.
At least three referees are asked to provide comments on each protocol. In general these will be: a person with experience ofCochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, buteditors may be asked to provide referee comments for protocols other than those for which they have editorial responsibility.
In the case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees.
Once comments from referees have been returned to the author, the author is asked to modify the protocol as appropriateand return this to the Review Group Co-ordinator (by submitting it for editorial process through Archie) with a commentary ofthe changes made and how these address the referees' comments.
Referees will be sent copies of the other referees' comments and the author's response, once the protocol is approved forpublication.
Once approved by the contact editor, the editorial team will check and approve the protocol. Final approval for publication willbe given by the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group at the protocol stage.
The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authorsthemselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event anissue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.
Time between submission of protocol and receipt of the completed review should normally be two years or less. After
this time, protocols will be judged to have 'expired' and will be removed from the Cochrane Library with a note to that effect in
the What's New section.
Reviews
The UGPD Group editorial team supports authors in the preparation of reviews by providing methodological advice,
formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials
such as the handbook for authors and training and support as required on an ad hoc basis. Informal advice is available
through the Review Group Co-ordinator.
At least three referees are asked to provide comments on each review, in general these will be: a person with experience ofCochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, buteditors may be asked to provide referee comments for reviews other than those for which they have editorial responsibility. Inthe case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees.
Where possible, comments will be sought from the same peer referees who commented on the protocol.
After comments from referees have been returned to the authors, the authors are asked to modify the review as appropriateand return it to the Review Group Co-ordinator with a commentary of the changes made and how these address the referees'comments.
Once approved by an editor, the editorial team will check and approve the review. Final approval for publication will be givenby the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group but completed reviews are submittedto Wiley's copy editing service and authors will be expected to amend their reviews to reflect these copy edit comments before Cochrane Upper Gastrointestinal and Pancreatic Diseases Group The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authorsthemselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event anissue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.
Referees will be sent copies of the other referees' comments and the author's response, once the review is approved forpublication.
Updating
Review authors will obtain newly identified information which may be relevant to their review from the specialised register on
an annual basis.
Reviews will be updated annually when new studies are identified. If no new trials are found at the annual update search, anote will be made on the published review to this effect.
Updates of reviews will not normally be subject to the peer referee process as described for reviews unless the conclusions ofthe review are substantially altered by the addition of new data.
Feedback
Brendan Delaney is the Feedback Editor appointed by the UGPD, and will oversee the process of dealing with comments and
criticisms.
Out of date reviews
Policy to be developed.
Disagreements about updates
The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authors
themselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event an
issue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.
Plagiarism
The Group upholds an author's right to intellectual property and will not tolerate plagiarism. Authors are requested to properly
cite or paraphrase another author's work. Copying and pasting the work of others is not acceptable. Authors are expected to
create original text and analyses. The Group has procedures in place to detect plagiarism at all stages of review development,
including title registration. Authors suspected of plagiarism will be confronted. Depending on the severity of plagiarism an
author may be given guidance on how rephrase or quote another's work or, in extreme cases, banned from any further work
with the group.
Publications
Arnott S. et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data. Int. J.
Radiation Oncology Biol. Phys., 41 (3)579- 583. Also published as: Preoperative radiotherapy for esophageal carcinomaTierney J. et al. The Cochrane Library.
Calvet X., Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic treatment following epinephrineinjection improves outcome in high-risk bleeding ulcers. Gastroenterology 2004; 126: 441-450.
Delaney B. et al. The management of dyspepsia: a systematic review. Health Technology Assessment 2000; 4(39). Thispublication incorporates details of several Cochrane reviews.
Delaney B. Managing dyspepsia and reflux. The Practitioner 2003;247:408-411 Delaney BC. et al. Helicobacter pylori infection. Clinical Evidence 2001; 5:324-337.
Delaney BC. et al. Helicobacter pylori infection. Clinical Evidence 2002; 7: 414-428. (update) Delaney BC. et al. Helicobacter pylori infection. Clinical Evidence 2002; (update in press for issue 8) Delaney BC, Moayyedi P. Dyspepsia. In: Health Care Needs Assessment 3rd Series. Edited by Stevens A, Raftery J, Mant J.
Routledge, 2003(in press) also available at: http://hcna.radcliffe-oxford.com/dysframe.htm Delaney BC, O'Morain C. The management of dyspepsia. The Year in Helicobacter pylori. Current Opinion inGastroenterology 2001;17 (1):S38-S42.
Delaney BC. Dyspepsia and Peptic Ulcer Disease. In: Quality indicators for General Practice. (eds.) Marshall M, Campbell S, Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Hacker J, Roland M. Royal Society of Medicine; London, 2001.104-111. [Book chapter] Delaney BC. Dyspepsia management in the millennium: to test and treat or not? Gut 2003; 52:10-11.
Delaney BC. Helicobacter pylori. Best Treatments 2002 (electronic media): www.besttreatments.org) Delaney BC. Making sense of all the dyspepsia Guidelines. Pulse. March 24th 2001; 60-68.
Delaney BC. Managing uninvestigated dyspepsia. Best of DDW CD ROM. Digestive Disease Week 2002. (electronic mediaCD ROM).
Delaney BC. Modelling H. pylori 'test and treat' in Primary Care. European Journal of General Practice 2001;7:129-131.
[Editorial] Delaney BC. Modern diagnosis and management of dyspepsia. Member's reference book 2001. Royal College of GeneralPractitioners; London, 2001:63-64.
Delaney BC. Test and treat for H.pylori. Gastroimpact: Shire Health; London Autumn 2002: 14-15.
Delaney B C and Moayyedi P. Eradicating H.pylori does not cause gastro-oesophageal reflux disease. BMJ 2004; 328: 1388 -1389. [Editorial] Dent J, Armstrong D, Delaney B, Moayyedi P, Talley N J, and Vakil N. Symptom evaluation in reflux disease Proceedings of aworkshop held in Marrakech, Morocco Symptom evaluation in reflux disease: workshop background, processes, terminology,recommendations, and discussion outputs. Gut 2004; 53 (Suppl 4): iv1-iv24.
Ford A, Delaney B. Managing Gastro-oesophageal reflux disease. Update. Nov. 2002; 4-6.
Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease:systematic review and economic analysis. Am J Gastroenterol. 2004; 99: 1833-55.
Fraser A, Delaney BC, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: A systematic review.
American Journal of Gastroenterology 2004 (in press) Gilbert R. et al. Cisapride for GORD in infants. Journal of Paediatrics and Child Health, 2000; 36:524-529. Also published asCisapride treatment for gastro-oesophageal reflux in children Augood C et al. The Cochrane Library.
JP Gisbert, S Khorrami, F Carballo, X Calvet, E Gene, E Dominguez-Muñoz. Meta-analysis: Helicobacter pylori eradicationtherapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. AlimentPharmacol Ther 2004; 19: 617-629.
Jankowski J. et al. 10 minute consultation: Gastro-oesophageal reflux disease (GORD). BMJ 2002;325:945 Katzka D. et al. Gastro-oesophageal reflux disease. Clinical Evidence 2000; Issue 4:253-265.
Logan RFA, Delaney BC. Implications of dyspepsia for the NHS. In: ABC of the Upper Gastrointestinal tract. (eds) LoganRPH, Harris A, Misiewicz JJ, Baron JH. BMJ Books; London, 2002. ISBN 0-7279-1266-6.
Moayyeddi P. et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcerdyspepsia. BMJ 2000, 321:659-664. Also published as Eradication of Helicobacter pylori for non-ulcer dyspepsia Moayyedi Pet al. The Cochrane Library.
Moayyedi P. et al. Helicobacter pylori eradication therapy for nonulcer dyspepsia. Annals of Internal Medicine 2002; 136: 555-6.
Moayyedi P. et al. Systematic review: antacids, H2 receptor antagonists, prokinetics, bismuth and sucralfate therapy for nonulcer dyspepsia. Alimentary Pharm and Ther 2003;17:1215-1227.
Moayyedi P. et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003; 17: 1207-14.
Moayyedi P, Delaney B, Forman D. Gastro-oesophageal reflux disease. Clinical Evidence 2003; 9: 89-91.
Moayyedi P. Helicobacter pylori eradication in non-ulcer dyspepsia: the case for. In: Helicobacter pylori: Basic mechanisms toclinical cure 2002. Eds. Hunt RH, Tytgat GNJ. Kluwer Academic Publishers, Dordrecht 2002; 265-274.
Moayyedi P, Delaney BC, Katzka D, Forman D. Gastro-oesophageal reflux disease. Clinical Evidence 2000; issue 4: 253-265 Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylorieradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Moayyedi P, Soo S, Deeks J, Forman D, Harris A, Innes M, Delaney B. Systematic review: antacids, H2-receptor antagonists,prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics 2003; 17:1207-14.
Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ, The efficacy of proton pump inhibitors in nonulcer dyspepsia: Asystematic review and economic analysis. Gastroenterology 2004; 127:1329-37.
Moayyedi P, Duffy J, Delaney B. Symptom evaluation in reflux disease Proceedings of a workshop held in Marrakech,Morocco New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut 2004; 53 (Suppl 4): iv55-iv57.
Rostom A. et al. Canadian co-ordination office for health technology assessment. Gastroduodenal ulcers associated with theuse of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Due forpublication in September 2003 Rostom A. et al. Prevention of NSAID-induced upper GI toxicity. (manuscript submitted to Rheumatology) Also published asPrevention of NSAID-induced gastroduodenal ulcers Rostom A et al. The Cochrane Library.
Rostom, G. et al. The prevention of NSAID Induced Upper Gastrointestinal Toxicity: A meta-Analysis of Randomizedcontrolled Trials. J of Rheum sept. 2000; 27(9):2203-14.
Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. Symptom evaluation in reflux disease Proceedings ofa workshop held in Marrakech, Morocco A systematic review of symptomatic outcomes used in oesophagitis drug therapytrials. Gut 2004; 53 (Suppl 4): iv58-iv65.
Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am JGastroenterol. 2004; 99: 1817-22.
Soo S. et al. A systematic review of pharmacological therapies in non-ulcer dyspepsia. Gut 2000; 46: (suppl 11): A88 Soo S. A systematic review of pharmacological therapies in non-ulcer dyspepsia. Digestive Disease Week, San Diego, USA2000 (Gastroenterology 2000; 118: A440) Talley NJ, Marshall BJ, Bytzer P, Engstrand L, de Boer W, Vakil N, Delaney B, Jones R, Malfertheiner P, Agréus L.
Management Issues in Dyspepsia: Current Consensus and Controversies. Scandinavian Journal of Gastroenterology (inpress) Van Binsbergen JJ. et al. Nutrition in Primary Care: scope and relevance of output from the Cochrane Collaboration.
American Journal of Clinical Nutrition. 2003;77: 1083-1088.
Van Pinxteren B. et al. GERD in primary care. (manuscript in preparation). Also published as Short-term treatment with protonpump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopynegative reflux disease van Pinxteren B et al. The Cochrane Library.
van Pinxteren B. et al. Short-term Treatment of Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis ofthe Effect of Acid Suppressant Drugs. J Gen Int Med 2003, accepted van Pinxteren B. et al. (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabinefor the treatment of pancreatic cancer. Health Technology Assessment Monographs 5:(24).
Delaney B. et al. Effectiveness of prompt endoscopy in the management of dyspepsia: a systematic review. Digestive DiseaseWeek, Atlanta USA, 20-23 May 2001.
Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: addingcost information to a systematic review of the effectiveness of Helicobacter pylori eradication for non-ulcer dyspepsia. 3rd.
Symposium on systematic reviews, Oxford July 4-6 2000.
Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: addingcost information to a systematic review of the effectiveness of Helicobacter pylori eradication for non-ulcer dyspepsia.
European Society for Medical Decision Making ASM. Leiden, Netherlands June 16th. 2000.
Delaney B. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of theeffectiveness of Helicobacter pylori eradication for non-ulcer dyspepsia. 9th Cochrane Colloquium, Cape Town, South Africa.
October 21-29th 2000.
Delaney B. et al. Cost-Effectiveness of Early Endoscopy for Dyspepsia in Patients of 50 Years of Age and Over: Results of a Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Primary Care Based Randomised Controlled Trial. Digestive Disease Week, San Diego USA, 20-24 May 2000.
Delaney BC, Moayyedi P. Cost-effectiveness of maintenance therapies for oesophagitis: a 2nd order monte carlo simulationbased on a meta-analysis. Society for Medical Decision Making. Chicago, Illinois, USA. October 18-22nd 2003. (Oral) Delaney BC, Barton PM, Moayyedi P, Wilson S. A Discrete Event Simulation Of The Cost-Effectiveness Of Detecting UpperGi Cancer By Prompt Endoscopy In Dyspeptic Patients Above Different Ages. Society for Medical Decision Making. Chicago,Illinois, USA. October 18-22nd 2003. (Poster) Delaney BC, Qume M, Ford A, O'Rourke K, Moayyedi P, The management of dyspepsia in primary care: a prospectiveindividual patient data meta-analysis of health economic RCTs. Cochrane Colloquium, Barcelona, Spain 25th-31st October2003. (poster) Delaney BC, Moayyedi P, Mason M. Using Cochrane Reviews And Modelling In The Development Of UK National GuidelinesOn Dyspepsia. Cochrane Colloquium, Barcelona, Spain 25th-31st October 2003. (Oral) Delaney BC, Qume M, Ford A, Moayyedi P, on behalf of the Dyspepsia Trials Collaborators' Group. The management ofdyspepsia in primary care: a prospective individual patient data meta-analysis of health economic RCTs. European SocietyFor Medical Decision Making, Rotterdam June 2004 (Poster) Delaney BC, Moayyedi P, Mason M.Using Cochrane Reviews And Modelling In The Development Of UK National GuidelinesOn Dyspepsia. European Society For Medical Decision Making, Rotterdam June 2004 (Poster) Delaney BC, Ford A, Qume M, Moayyedi P,. Test and treat v.prompt endoscopy: an individual patient data meta-analysis.
North American Primary Care Research Group, Orlando, USA 12th Oct 2004. (Oral) Delaney BC, Ford A, Qume M, Moayyedi P. Test and treat v.prompt endoscopy: an individual patient data meta-analysis.
Society for Medical Decision Making, Atlanta, USA 19th Oct 2004. (Poster) Ford A, Qume M, Moayyedi P, Delaney BC. Test and treat v.prompt endoscopy: an individual patient data meta-analysis.
Digestive Disease Week New Orleans, USA 19th May 2004. (Oral) Gisbert, J. H. pylori (HP) Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of RecurrentBleeding (RB) from Peptic Ulcer (PU): a Cochrane Systematic (Helicobacter 2004; 9: 567) Gisbert J.P., Khorrami S., Carballo F., Calvet X., Gene E., Dominguez-Muñoz E., Pajares J.M., H. pylori (HP) EradicationTherapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding (RB) from Peptic Ulcer (PU): aCochrane Systematic Review. Gastroenterology 2004; 126 (Suppl.2): T1185. Presented in the last European HelicobacterStudy Group Congress in Vienna has been awarded as "Poster of Distinction".
Innes M.A. et al. Managing dyspepsia in primary care: a systematic review. Association of University Departments of GeneralPractice, Annual Scientific Meeting, London 1999.
Innes M.A. et al, Managing dyspepsia in Primary Care: A systematic review. Gastroenterology 2000; 118 Suppl 2: A1249.
Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Cochrane collaboration systematic review and meta-analysis of protonpump inhibitor treatment for peptic ulcer bleeding. Gut 2003; 52 (Suppl IV): A18 11th United European GastroenterologyWeek, Madrid, 1-5 November 2003.
Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Influence of geographical location of randomized controlled trials oneffectiveness of PPI treatment in ulcer bleeding: A post hoc analysis of a Cochrane Collaboration systematic review.
Gastroenterology 2004, 126: A-192 105th Annual meeting of the American Gastroenterological Association, DigestiveDiseases Week, New Orleans, LA, May 2004 Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Efficacy of PPI treatment for ulcer bleeding when compared withplacebo or an H2-receptor antagonist: A sub-group analysis from the Cochrane Collaboration systematic review.
Gastroenterology 2004; 126: A-193 105th Annual meeting of the American Gastroenterological Association, DigestiveDiseases Week, New Orleans, LA, May 2004 Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Does the efficacy of PPI treatment for ulcer bleeding depend on thenature of pre-randomization endoscopic stigmata? A post hoc analysis from the Cochrane Collaboration systematic review.
Gastroenterology 2004; 126: A-603 105th Annual meeting of the American Gastroenterological Association, DigestiveDiseases Week, New Orleans, LA, May 2004 Leontiadis G I, McIntyre L, Sharma V K, Howden C W. The influence of PPI dose on treatment efficacy for ulcer bleedingfollowing endoscopic emostatic therapy: A sub-group analysis from the Cochrane Collaboration systematic review.
Gastroenterology 2004; 126: A-602 105th Annual meeting of the American Gastroenterological Association, DigestiveDiseases Week, New Orleans, LA, May 2004 Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Moayyedi P. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcerdyspepsia (NUD) British Society of Gastroenterology, Birmingham, UK 2000 (Gut 2000; 46 (suppl 11): A51 Moayyedi P. et al. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD). Gastroenterology 2000; 118: A471 Moayyedi P. et al. Markov modelling with probabilistic sensitivity analysis based on meta-analysis: cost-effectiveness ofHelicobacter pylori eradication for non-ulcer dyspepsia. Society for Medical Decision Making, 22nd Annual Scientific Meeting,Cincinnatti, USA. September 24-27th 2000. (Poster presentation) van Pinxteren B. et al. Short-term Treatment with Proton Pump inhibitors, H2-receptor antagonists and Prokinetics inGastroesophageal Reflux Disease: A systematic review. Poster Presentation at DDW 2000, San Diego CA, USA, May 222000 (abstract published in Gastroenterology).
Wong, K.S.R. Is combination radiotherapy chemotherapy (RTCT) superior to radiotherapy (RT) alone in the non-surgicalmanagement of localized esophageal carcinoma? A systematic review. (abstr) Suppl Clin Inv Med 372 S50 1999. RoyalCollege of Physicians and Surgeons of Canada.Montreal, Quebec. September 1999.
Wong K.S.R. Meta-analysis of Combined Chemotherapy and Radiotherapy for Esophageal Cancer. ASTRO, AmericanSociety of Therapeutic Radiation Oncology. San Antonio, TX. September 1999.
Plenaries and WorkshopsBriggs A, Delaney BC; Schulpher M, Claxton K. Stochastic cost-effectiveness modelling. Society for Medical Decision Making.
Chicago, Illinois, USA. October 21st 2003. (invited postgraduate course) Delaney B.C. The role of quality of life measurement in the clinical assessment of GERD. Symptom assessment in refluxdisease. Marrakech, Morocco, 7-8th September 2002.
Delaney B.C. Test and treat strategies for H.pylori in the management of dyspepsia. Chris Silagy memorial lecture: Theimpact of systematic reviews on primary care. Kellog College, Oxford. 26th Sept 2002.
Delaney B.C. 'Pragmatic' RCTs : planning, conduct and analysis of RCTs with cost-effectiveness as the primary outcome.
Epidemiology Grand Round, McGill University Health Centre, Montreal Canada, October 8th 2002.
Delaney B.C. A Bayesian approach to dyspepsia: working with uncertainty at the interface between research and practice.
Invited lecture, Montreal, Canada 8th October 2002.
Delaney B.C. The Cochrane Collaboration and the evidence-base for managing dyspepsia. Gastroenterology Grand Round,Montreal General Hospital, Montreal, Canada. 9th October 2002.
Delaney B. Effectiveness of empirical treatments for undiagnosed dyspepsia. Primary Care Society for GastroenterologySymposium at The British Society of Gastroenterology ASM, Birmingham, March 21-23, 2000.
Delaney B. Evidence-based management of dyspepsia. Primary Care Society for Gastroenterology ASM, Birmingham,October 13th 2000.
Delaney B. Vale L. Exploring uncertainty in economic analysis: ways of extending systematic reviews to address issues ofcost-effectiveness. 9th Cochrane Colloquium, Cape Town, South Africa. October 21-29th 2000. (Invited Workshop) Delaney BC. Managing dyspepsia in primary care. XVIth International Workshop Gastrointestinal Pathology and Helicobacter.
Stockholm 4-6 September 2003.
Delaney BC. Prevalence and epidemiology of GERD. Europe-Japan Joint Expert meeting, London, 22nd Sept 2003.
Delaney BC. Managing dyspepsia in Primary Care A new Cochrane individual patient data meta-analysis. (AGA SpecialSymposium) Digestive Disease week, New Orleans, USA 19th May 2004.
Delaney BC. Management of Dyspepsia. (invited talk) WONCA-Europe, Amsterdam 3 June 12004.
Delaney BC. Dyspepsia management: H pylori and beyond (invited talk). United European Gastroenterology week, Prague27th Sept 2004.
Delaney BC. Approach to the patient with dyspepsia (lunch session). United European Gastroenterology week, Prague 28thSept 2004.
Delaney BC. Dyspepsia: Test and treat. Takeda Satellite symposium:United European Gastroenterology week, Prague 28thSept 2004 Delaney BC. Acute management of the patient with Gastroesophageal reflux disease: Workshop on Gastrointestinal Disease,Paris 21st Oct 2004 Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Incorporation of reviews into guidelines/discussion of reviews at meetings (e.g. consensus conferences) NHS Executive Evidence Review: "Improving Outcomes in Upper GI Cancers". This evidence review has been published andused by the NHS Centre for Research and Development in the development of their manual: "Guidance on CommissioningCancer Services: Upper GI Cancer". The Manual will, in turn, be used by Health Authorities to provide guidance in thecommissioning of relevant services.
The review "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophagealreflux disease-like symptoms and endoscopy negative reflux disease" will be included in primary care guidelines by theEuropean Society for Primary Care Gastroenterology.
The HTA Report: "Managing the Dyspeptic Patient" will be used as the evidence base for the production of guidelines by theBritish Society of Gastroenterology.
Dr R. Malthaner (UGPD editor and reviewer) and Dr Wong (UGPD reviewer) are contributing reviews of chemo- orradiotherapy as adjuvant or neoadjuvant therapy for oesophageal resectable cancer and took the lead in drafting and revisingthe Cancer Care Ontario Practice Guidelines Initiative, recently submitted to "Cancer Practice and Control".
Tierney, J The results of the pre-op RT in oesophageal cancer are included in the British Columbia Cancer Agency CancerManagement Guidelines for Gastrointestinal Cancer.
http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gastrointestinal/01.EsophagusAndCardia/Management/LocalizedDisease.htm References
Additional information

Source: http://ugpd.cochrane.org/sites/ugpd.cochrane.org/files/uploads/Module/2010_5_UGPD_module.pdf